The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk

被引:42
|
作者
Garcia-Guzman, M [1 ]
Larsen, E [1 ]
Vuori, K [1 ]
机构
[1] Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA
关键词
kinase; oncogenesis; signal transduction; tyrosine phosphorylation;
D O I
10.1038/sj.onc.1203750
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocyte growth factor triggers a complex biological program leading to invasive cell growth by activating the c-Met receptor tyrosine kinase. Following activation, Met signaling is elicited via its interactions with SH2- containing proteins, or via the phosphorylation of the docking protein Gab1, and the subsequent interaction of Gab1 with additional SH2-containing effector molecules. We have previously shown that the interaction between phosphorylated Gab1 and the adaptor protein Crk mediates activation of the JNK pathway downstream of Met. We report here that c-Cbl, which is a Gab1-like docking protein, also becomes tyrosine-phosphorylated in response to Met activation and serves as a docking molecule for various SH2-containing molecules, including Crk. We further show that Cbl is similarly capable of enhancing Met-induced JNK activation, and several lines of experimentation suggests that it does so by interacting with Crk. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Taken together, our studies demonstrate a previously unidentified functional role for Cbl in Met signaling and suggest that Met utilizes at least two docking proteins, Gab1 and Cbl, to activate downstream signaling pathways.
引用
收藏
页码:4058 / 4065
页数:8
相关论文
共 26 条
  • [1] The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk
    Miguel Garcia-Guzman
    Elise Larsen
    Kristiina Vuori
    Oncogene, 2000, 19 : 4058 - 4065
  • [2] The product of the proto-oncogene c-cbl: A negative regulator of the Syk tyrosine kinase
    Ota, Y
    Samelson, LE
    SCIENCE, 1997, 276 (5311) : 418 - 420
  • [3] Interaction of the c-cbl proto-oncogene product with the Tyk-2 protein tyrosine kinase
    Uddin, S
    Gardziola, C
    Dangat, A
    Yi, TL
    Platanias, LC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 225 (03) : 833 - 838
  • [4] The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases
    Broome, MA
    Galisteo, ML
    Schlessinger, J
    Courtneidge, SA
    ONCOGENE, 1999, 18 (18) : 2908 - 2912
  • [5] The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases
    Martin A Broome
    Maria L Galisteo
    Joseph Schlessinger
    Sara A Courtneidge
    Oncogene, 1999, 18 : 2908 - 2912
  • [6] THE C-CBL PROTO-ONCOGENE IS PREFERENTIALLY EXPRESSED IN THYMUS AND TESTIS TISSUE AND ENCODES A NUCLEAR-PROTEIN
    LANGDON, WY
    HYLAND, CD
    GRUMONT, RJ
    MORSE, HC
    JOURNAL OF VIROLOGY, 1989, 63 (12) : 5420 - 5424
  • [7] The product of the proto-oncogene, c-cbl, regulates PLCγ1 activation after T cell receptor engagement.
    Graham, LJ
    Stoica, B
    DeBell, KE
    Bonvini, E
    Rellahan, BL
    FASEB JOURNAL, 1998, 12 (05): : A937 - A937
  • [8] D-Cbl, the Drosophila homologue of the c-Cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking C-terminal adaptor binding sites
    Gary R Hime
    Mukunda Pai Dhungat
    Ashley Ng
    David DL Bowtell
    Oncogene, 1997, 14 : 2709 - 2719
  • [9] D-Cbl, the Drosophila homologue of the c-Cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking C-terminal adaptor binding sites
    Hime, GR
    Dhungat, MP
    Ng, A
    Bowtell, DDL
    ONCOGENE, 1997, 14 (22) : 2709 - 2719
  • [10] α1-adrenoceptor subtype activation increases proto-oncogene mRNA levels.: Role of protein kinase C
    García-Sáinz, JA
    Alcántara-Hernández, R
    Vázquez-Prado, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 342 (2-3) : 311 - 317